Introduction
Artificial intelligence (AI) investigation, particularly deep learning for medical image processing, has recently experienced an increase in interest and progress. Since imaging is critical for diagnosing lung disorders, many artificial intelligence techniques have been developed for chest imaging. AI is ideal for a range of activities and objectives in the field of chest radiology, including initial evaluation or triage of specific diseases, detection, and diagnosis, quantitative assessment of disease severity and monitoring, and prediction for decision support. Although AI is a powerful technology that may be utilized in medical imaging and is expected to advance clinical practice, there are significant limitations that need to be overcome before AI can be properly integrated into workflows. To be effective in the modern age of AI, radiologists and clinicians need to learn and become aware of the current state, future clinical applications of AI in chest imaging, and ongoing issues.
What Is Artificial Intelligence Imaging?
Artificial intelligence (AI) is a game-changing technology that uses computerized algorithms to analyze complex data. Diagnostic imaging is one of the most potential clinical applications of AI, with increasing emphasis on establishing and fine-tuning its performance to assist in the identification and quantification of a wide range of clinical problems. The use of artificial intelligence (AI) technology in imaging, such as cancer screening, is one of the most cutting-edge applications of AI in healthcare today. The adoption of AI could dramatically enhance disease prevention, early detection, and treatment, allowing better care and speedier treatment.
What Is Lung Disease?
The lung disease encompasses a wide range of conditions that impact the functioning of the lungs. These disorders include asthma, chronic obstructive pulmonary disease (COPD), respiratory infections such as influenza, pneumonia, tuberculosis, lung cancer, and several other respiratory complications. Certain pulmonary conditions have the potential to result in respiratory failure. The cause of the majority of lung disorders can be attributed to smoking, infections, and genetic factors. The lungs are an integral component of a complex physiological system, undergoing numerous cycles of expansion and relaxation on a daily basis in order to facilitate the intake of oxygen and the expulsion of carbon dioxide. The occurrence of lung illness can arise from complications affecting several components of the respiratory system.
What Are the Numerous Applications of AI in Pulmonary Obstructive Disease?
-
COPD: Artificial intelligence and deep learning may screen patients for COPD, but spirometry is the gold standard for diagnosis. Deep residual networks can detect COPD in smokers and ex-smokers who have not been found by low-dose CT (computed tomography) lung screening. AI is also used to evaluate COPD patients. This started many studies that related COPD traits to genetic and molecular mechanisms and predicted disease progression for distinct COPD subtypes. AI-based tools may also help people identify home exacerbations and when to seek medical assistance.
-
Asthma: An obstructive lung illness with a variety of manifestations, asthma is intermittent and treatable. Artificial intelligence (AI) may enhance diagnosis, phenotypic classification, asthma exacerbation prediction, and therapy response. The highest corticosteroid-responsiveness phenotype in terms of phenotype categorization was found in patients with reduced pulmonary function, high serum eosinophils, nasal polyps, and late-onset asthma when applying the machine learning approach, as well as cluster analysis. Young, obese females with early-onset asthma were also shown to have this particular profile of corticosteroid response.
What Are the Applications of AI for Interstitial Pulmonary Disease?
Interstitial lung disease (ILD) comprises all disease conditions that can cause pleural or parenchymal inflammation and scarring. Using HRCT (high-resolution computed tomography) chest images, deep learning algorithms can aid with the diagnosis of ILD. Similarly, deep learning improves the accuracy of diagnosing chronic hypersensitivity pneumonitis, cryptogenic organizing pneumonia, nonspecific interstitial pneumonia, and typical interstitial pneumonia patterns. The AI algorithms used to evaluate HRCT images of individuals with interstitial pulmonary fibrosis have quantified airway volumes and parenchymal lesions with great success.
What Are the Diagnostic Applications of Artificial Intelligence in the Context of Lung Infections?
-
Tuberculosis: In many nations, tuberculosis (TB) is a leading cause of death. Diagnosis is complicated due to the variety of chest radiographic presentations of tuberculosis. Different CAD (computer-aided design) algorithms have been developed by researchers to detect cavitary and focal TB radiographs. AI can help in TB treatment in addition to diagnosis. AI may aid in the evaluation of records, the identification of clinical trends, surveillance, and the identification of factors that may lead to TB treatment and medication adherence failure.
-
COVID-19: Global morbidity and death have grown as COVID-19 (coronavirus of 2019) therapies have been tested. AI algorithms can diagnose and prognosis COVID-19 patients. A COVID-19 detection neural network was used to differentiate CT results of COVID-19 infection from community-acquired pneumonia. The use of a deep learning convolutional neural network to assess radiographic parameters in order to stage COVID-19 infection aids in early disease prognosis and treatment options. Deep learning algorithms are used to recognize protein shapes and forms. The data from this aided in the development of the COVID-19 vaccine.
What Are AI Diagnoses in Malignancy?
Pulmonary malignancies are classified by the World Health Organisation as one of the most dangerous types of solid tumors, regardless of recent advancements in therapy. Enhancing patient outcomes necessitates the timely and accurate identification of medical conditions. Computer-aided design (CAD) systems employ deep learning algorithms to assist radiologists in the segmentation of computed tomography (CT) images for the purpose of detecting and categorizing nodules. The neural network training methodology employs statistical finite element analysis or three-dimensional lung segmentation techniques. The application of neural network approaches has been found to enhance the positive predictive value of lung cancer detection in chest digital tomosynthesis. The ability of deep learning to accurately differentiate between malignant and benign nodules is limited due to the absence of universally applicable features.
What Are the Different Challenges?
The advent of artificial intelligence in biomedical imaging may have a potentially revolutionary effect on a number of activities, including early diagnosis, prognosis, and lung cancer treatment planning. Once implemented in clinical practice, this will significantly enhance the management of patients. Nevertheless, the widespread implementation of AI-based tools in daily work is currently hampered by a number of barriers.
-
The creation of AI-based instruments requires a vast quantity of high-quality data. Despite the widespread availability of lung cancer datasets, imaging, clinical, and laboratory data should be compiled in a highly standardized and organized fashion to enable the development of robust algorithms.
-
Collaboration is a concept in AI research for medical applications, as the development of effective models with a real impact on daily clinical practice necessitates the work of multidisciplinary teams consisting of radiologists, physicians, engineers, and software developers who share their knowledge in a way that is mutually beneficial and multidirectional.
-
Another significant limitation relates to the design of the investigation.
-
Reproducibility is one of the primary obstacles that AI must surmount in order to achieve clinical implementation, as there are numerous differences between studies and research institutions in every aspect of the radiomics workflow.
-
The imaging characteristics and values between patients may be attributable to acquisition parameters and not to differences in tissue biology. The exclusion of features that are heavily influenced by acquisition and reconstruction parameters can be used to circumvent this limitation.
What Are the Emerging Applications?
-
Multi-Omics - AI and multi-omics are starting to demonstrate tremendous promise in the fight against difficult-to-treat conditions like cancer. Researchers can better grasp the complex nature of different cancer kinds and develop more specialized and efficient treatments by utilizing AI to evaluate multi-omics data.
-
Lung Microbiome - The lung microbiota affects lung cancer development, prognosis, and treatment. It also affects lung cancer histological subgroups. Large-scale microbiome and metabolome data collection has been conducted due to its significance in illness progression. To process and analyze ‘big data,’ machine learning technologies and image-based biomarkers from WSIs present promising opportunities.
-
3D Pathology - A new imaging technology used in DP operations is 3D (three-dimensional) microscopy. The non-destructive method and capacity to analyze bigger tissue samples can address spatial and temporal heterogeneity concerns. Currently, it improves prostate cancer risk stratification. 3D microscopy and DP can recreate complete tissue blocks to study cell types of spatial interactions, making them valuable pathology tools.
-
Predicting Transplant Rejection - Clinical criteria alone are imprecise, making it difficult for clinicians to anticipate graft rejection, a primary cause of lung transplant mortality. Transplant patients show unique morphological patterns connected to lymphocytes and stroma to predict transplant rejection in machine learning models. In the future, lung transplant recipients may use similar methods.
-
Drug Discovery and Development - Drug development for pulmonary illnesses such as IPF and pulmonary artery hypertension has resumed to meet unmet medical requirements. The prediction of the effectiveness and adverse effects of possible therapeutic compounds is a significant utilization of artificial intelligence (AI) in the field of medicinal chemistry. The conventional methodologies employed in drug discovery frequently depend on arduous and protracted experimental procedures for evaluating the possible physiological impacts of a chemical on the human organism. Scoring systems that may incorporate manual histopathology slide assessment are essential for estimating novel agent responses. Automated image data processing by computational methods speeds up the process.
Conclusion
AI has the potential to transform lung cancer detection and therapy. Radiological imaging is at the forefront of early lung cancer detection, treatment, and follow-up. AI algorithms based on imaging data may uncover new predictive and prognostic biomarkers, improving lung cancer patient outcomes. The use of numerous sources of knowledge and complete models may aid in the classification of lung cancer. These systems must be used in clinical practice; however, there are various obstacles to overcome. As demonstrated, the creation of AI tools necessitates enormous data sets, much as radiologists, clinicians, and AI experts must collaborate to ensure the clinical transition. Collaboration across institutions is more important than ever. Guidelines should be used to guide the structure and reliability of AI-based research. Although AI is unlimited, its application in clinics could contribute to individualized treatment. Radiologists and doctors must comprehend the current state of AI, its clinical utility, and the issues in chest imaging.
